BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 25961927)

  • 21. Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.
    Stratikopoulos EE; Dendy M; Szabolcs M; Khaykin AJ; Lefebvre C; Zhou MM; Parsons R
    Cancer Cell; 2015 Jun; 27(6):837-51. PubMed ID: 26058079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion.
    Wang H; Sharma L; Lu J; Finch P; Fletcher S; Prochownik EV
    Oncotarget; 2015 Jun; 6(18):15857-70. PubMed ID: 26036281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.
    Wedeh G; Cerny-Reiterer S; Eisenwort G; Herrmann H; Blatt K; Hadzijusufovic E; Sadovnik I; Müllauer L; Schwaab J; Hoffmann T; Bradner JE; Radia D; Sperr WR; Hoermann G; Reiter A; Horny HP; Zuber J; Arock M; Valent P
    Leukemia; 2015 Nov; 29(11):2230-7. PubMed ID: 26055303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma.
    Lee S; Rellinger EJ; Kim KW; Craig BT; Romain CV; Qiao J; Chung DH
    Surgery; 2015 Sep; 158(3):819-26. PubMed ID: 26067464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells.
    Alghamdi S; Khan I; Beeravolu N; McKee C; Thibodeau B; Wilson G; Chaudhry GR
    Stem Cell Res Ther; 2016 Feb; 7():22. PubMed ID: 26830473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling.
    Heinemann A; Cullinane C; De Paoli-Iseppi R; Wilmott JS; Gunatilake D; Madore J; Strbenac D; Yang JY; Gowrishankar K; Tiffen JC; Prinjha RK; Smithers N; McArthur GA; Hersey P; Gallagher SJ
    Oncotarget; 2015 Aug; 6(25):21507-21. PubMed ID: 26087189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
    Lu J; Qian Y; Altieri M; Dong H; Wang J; Raina K; Hines J; Winkler JD; Crew AP; Coleman K; Crews CM
    Chem Biol; 2015 Jun; 22(6):755-63. PubMed ID: 26051217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BET inhibitor resistance emerges from leukaemia stem cells.
    Fong CY; Gilan O; Lam EY; Rubin AF; Ftouni S; Tyler D; Stanley K; Sinha D; Yeh P; Morison J; Giotopoulos G; Lugo D; Jeffrey P; Lee SC; Carpenter C; Gregory R; Ramsay RG; Lane SW; Abdel-Wahab O; Kouzarides T; Johnstone RW; Dawson SJ; Huntly BJ; Prinjha RK; Papenfuss AT; Dawson MA
    Nature; 2015 Sep; 525(7570):538-42. PubMed ID: 26367796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
    Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
    Yao W; Yue P; Khuri FR; Sun SY
    Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
    Scott DW; Mottok A; Ennishi D; Wright GW; Farinha P; Ben-Neriah S; Kridel R; Barry GS; Hother C; Abrisqueta P; Boyle M; Meissner B; Telenius A; Savage KJ; Sehn LH; Slack GW; Steidl C; Staudt LM; Connors JM; Rimsza LM; Gascoyne RD
    J Clin Oncol; 2015 Sep; 33(26):2848-56. PubMed ID: 26240231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism.
    Lu H; Xue Y; Yu GK; Arias C; Lin J; Fong S; Faure M; Weisburd B; Ji X; Mercier A; Sutton J; Luo K; Gao Z; Zhou Q
    Elife; 2015 Jun; 4():e06535. PubMed ID: 26083714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver.
    Costa-Silva B; Aiello NM; Ocean AJ; Singh S; Zhang H; Thakur BK; Becker A; Hoshino A; Mark MT; Molina H; Xiang J; Zhang T; Theilen TM; García-Santos G; Williams C; Ararso Y; Huang Y; Rodrigues G; Shen TL; Labori KJ; Lothe IM; Kure EH; Hernandez J; Doussot A; Ebbesen SH; Grandgenett PM; Hollingsworth MA; Jain M; Mallya K; Batra SK; Jarnagin WR; Schwartz RE; Matei I; Peinado H; Stanger BZ; Bromberg J; Lyden D
    Nat Cell Biol; 2015 Jun; 17(6):816-26. PubMed ID: 25985394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting bromodomain-containing protein 4 (BRD4) benefits rheumatoid arthritis.
    Zhang QG; Qian J; Zhu YC
    Immunol Lett; 2015 Aug; 166(2):103-8. PubMed ID: 26093279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.
    Duffy BC; Liu S; Martin GS; Wang R; Hsia MM; Zhao H; Guo C; Ellis M; Quinn JF; Kharenko OA; Norek K; Gesner EM; Young PR; McLure KG; Wagner GS; Lakshminarasimhan D; White A; Suto RK; Hansen HC; Kitchen DB
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2818-23. PubMed ID: 26022843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF.
    Bennett J; Fedorov O; Tallant C; Monteiro O; Meier J; Gamble V; Savitsky P; Nunez-Alonso GA; Haendler B; Rogers C; Brennan PE; Müller S; Knapp S
    J Med Chem; 2016 Feb; 59(4):1642-7. PubMed ID: 25974391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.